Beam Therapeutics Reports First Clinical Results From BEAM-301 Trial
Shares climbed more than 4% on Tuesday after Beam Therapeutics released the first clinical results from its BEAM-301 trial. H.C. Wainwright said the results strengthen its conviction in the platform.